Skip to content
You are not logged in |Login  
     
Limit search to available items
Your search query has been changed... Tried: (united and states. and federal and trade and commission. and division and of and industry and analysis) no results found... Tried: (united or states. or federal or trade or commission. or division or industry or analysis)
32000 results found. Sorted by relevance .
Record:   Prev Next
Resources
More Information
Bestseller
BestsellerE-book

Title Healthcare antitrust, settlements, and the Federal Trade Commission / edited by James Langenfeld, Edwin Galeano.

Publication Info. Bingley, UK : Emerald Publishing, 2018.

Item Status

Edition First edition.
Description 1 online resource.
Physical Medium polychrome
Description text file
Series Research in law and economics ; volume 28
Research in law and economics (Emerald Publishing (Firm)) ; v. 28.
Bibliography Includes bibliographical references and index.
Contents Front Cover; Healthcare Antitrust, Settlements, and the Federal Trade Commission; Copyright Page; Contents; About the Editors; List of Contributors; Acknowledgments; Introduction; "To Know Where You're Going, Look at Where You've Been"; Introduction; Pharmaceuticals: A Case of FTC Investment and Consumption; Provider Mergers: Clear Guidance from Litigated Cases; No Need for Special Rules for Healthcare Markets; ACKNOWLEDGMENT; Notes; References; Actavis, Authorized Generics, and the Future of Antitrust Law; Introduction; Background; Merits Analysis; Hatch-Waxman Background.
Applying Merits Analysis to Hatch-WaxmanPre-Actavis Analysis of Hatch-Waxman Settlements; Federal Trade Commission v. Actavis; Understanding Actavis; Bribing Generics to Stay Out of the Market; Hypotheticals; H1. The Litigants' Expectations about Litigation are Correct; H2. The Parties Both Believe that the Brand Holds a "Strong" Patent; H3. No Alignment in Expectations; H4. Pessimistic Litigants Split the Patent Life with No Net Reverse Payment; H5a. The Brand Prevailed in a Litigation Challenging Patent Validity but Settles a Second Challenge.
H5b. The Settlement Fails and the Parties Continue to LitigateH6. No Alignment in Expectations but Risk Aversion Leads to Settlements; H7a. Efficiencies; H7b. Efficiencies; Some Conclusions Derived from the Hypotheticals; Without Legal Limitations, There Will Be Anticompetitive Hatch-Waxman Settlements; Actavis Abandons the Preponderance-of-the-Evidence Standard for Determining Anticompetitive Effects; If the Parties' Expectations Are Correct, Absent Risk Aversion, on Average, Consumers Are Often No Better Off with the Acta ... ; Not Accounting for Risk Profiles May Harm Consumers.
Actavis Relies on Intent EvidenceActavis Relies on the Intent of the Brand, Not Necessarily the Generic; If the Parties' Expectations Are Not Correct, the Actavis Solution May Make Consumers Worse Off than Merits Analysis; Even in a Settlement without a Net Reverse Payment, One of the Parties May Intend to Achieve an Anticompetitive Effect; Actavis Circumvents Other Elements of Conventional Antitrust Analysis; A Red Flag Is Central to the Actavis Methodology; There Is No Easy Means of Balancing Efficiencies against Anticompetitive Effects Using the Actavis Methodology.
Additional Unresolved Actavis IssuesAntitrust Injury; Damages; The Slippery Slope of Mt. Actavis; The No-AG Agreement; Applying Actavis to Difficult IP/Antitrust Cases; Antitrust Guidelines for the Licensing of Intellectual Property; Actavis beyond the IP/Antitrust Interface; Where Are We Going?; Notes; Acknowledgment; References; Solving the Product-Hopping Conundrum through Safe Harbors and a No-Economic-Sense Test; Introduction; Product Hopping; Forms of Product Hopping; Hatch-Waxman Act; State Drug Product Selection Laws; Timing of Generic Entry; A New Product-Hopping Framework.
Summary This volume of Research in Law and Economics contains articles that address important legal and economic developments in the areas of healthcare, intellectual property and labor settlements, competitive effects, cartel overcharges, and the U.S. Federal Trade Commission (""FTC"").
Local Note eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - North America
Subject Antitrust law -- United States.
Antitrust law.
United States.
Medical care -- Law and legislation -- United States.
Medical care -- Law and legislation.
Genre/Form Electronic books.
Subject Medical care.
Added Author Langenfeld, James, editor.
Galeano, Edwin, editor.
Other Form: Print version: Healthcare antitrust, settlements, and the Federal Trade Commission. First edition. Bingley, UK : Emerald Publishing, 2018 1787566005 9781787566002 (OCoLC)1023605369
ISBN 9781787565999 (electronic book)
1787565998 (electronic book)
9781787566019
1787566013
9781787566002
1787566005